Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

412 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Angiographic outcomes with biodegradable polymer and permanent polymer drug-eluting stents.
Kufner S, Massberg S, Dommasch M, Byrne RA, Tiroch K, Ranftl S, Fusaro M, Schömig A, Kastrati A, Mehilli J; Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents Trial Investigators. Kufner S, et al. Among authors: byrne ra. Catheter Cardiovasc Interv. 2011 Aug 1;78(2):161-6. doi: 10.1002/ccd.22823. Epub 2011 Mar 11. Catheter Cardiovasc Interv. 2011. PMID: 21400652 Clinical Trial.
Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials.
Stefanini GG, Byrne RA, Serruys PW, de Waha A, Meier B, Massberg S, Jüni P, Schömig A, Windecker S, Kastrati A. Stefanini GG, et al. Among authors: byrne ra. Eur Heart J. 2012 May;33(10):1214-22. doi: 10.1093/eurheartj/ehs086. Epub 2012 Mar 24. Eur Heart J. 2012. PMID: 22447805 Free article.
Second-versus first-generation "Limus"-eluting stents in diabetic patients with coronary artery disease: a randomized comparison in setting of ISAR-TEST-4 trial.
Kufner S, Byrne RA, Mehilli J, Massberg S, Birkmeier KA, Schulz S, Pache J, Schömig A, Kastrati A. Kufner S, et al. Among authors: byrne ra. Catheter Cardiovasc Interv. 2013 Nov 15;82(6):E769-76. doi: 10.1002/ccd.24741. Epub 2013 Jun 11. Catheter Cardiovasc Interv. 2013. PMID: 23754254 Clinical Trial.
Impact of coronary anatomy and stenting technique on long-term outcome after drug-eluting stent implantation for unprotected left main coronary artery disease.
Tiroch K, Mehilli J, Byrne RA, Schulz S, Massberg S, Laugwitz KL, Vorpahl M, Seyfarth M, Kastrati A; ISAR-LEFT MAIN Study Investigators. Tiroch K, et al. Among authors: byrne ra. JACC Cardiovasc Interv. 2014 Jan;7(1):29-36. doi: 10.1016/j.jcin.2013.08.013. Epub 2013 Dec 11. JACC Cardiovasc Interv. 2014. PMID: 24332416 Free article. Clinical Trial.
Increased bleeding risk during percutaneous coronary interventions by arterial hypertension.
Ndrepepa G, Groha P, Lahmann AL, Lohaus R, Cassese S, Schulz-Schüpke S, Kufner S, Mayer K, Bernlochner I, Byrne RA, Fusaro M, Laugwitz KL, Schunkert H, Kastrati A. Ndrepepa G, et al. Among authors: byrne ra. Catheter Cardiovasc Interv. 2016 Aug;88(2):184-90. doi: 10.1002/ccd.26272. Epub 2015 Nov 3. Catheter Cardiovasc Interv. 2016. PMID: 26526702
Three-year efficacy and safety of new- versus early-generation drug-eluting stents for unprotected left main coronary artery disease insights from the ISAR-LEFT MAIN and ISAR-LEFT MAIN 2 trials.
Cassese S, Kufner S, Xhepa E, Byrne RA, Kreutzer J, Ibrahim T, Tiroch K, Valgimigli M, Tölg R, Fusaro M, Schunkert H, Laugwitz KL, Mehilli J, Kastrati A. Cassese S, et al. Among authors: byrne ra. Clin Res Cardiol. 2016 Jul;105(7):575-84. doi: 10.1007/s00392-015-0953-x. Epub 2015 Dec 22. Clin Res Cardiol. 2016. PMID: 26689707 Free article. Clinical Trial.
412 results